NanoString Technologies, Inc. (NSTG) News
Filter NSTG News Items
NSTG News Results
|Loading, please wait...|
NSTG News Highlights
- NSTG's 30 day story count now stands at 7.
- Over the past 6 days, the trend for NSTG's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about NSTG are HSKA, ABC and ABCM.
Latest NSTG News From Around the Web
Below are the latest news stories about NANOSTRING TECHNOLOGIES INC that investors may wish to consider to help them evaluate NSTG as an investment opportunity.
The analysts covering NanoString Technologies, Inc. ( NASDAQ:NSTG ) delivered a dose of negativity to shareholders...
SEATTLE, November 10, 2022--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast presentations from two upcoming healthcare conferences.
Analysts fell to the sidelines weighing in on Heska (HSKA – Research Report), NanoString Tech (NSTG – Research Report) and Revance Therapeutics (RVNC – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Heska (HSKA) In a report released today, Erin Wright from Morgan Stanley maintained a Hold rating on Heska, with a price target of $135.00. The company's shares closed last Wednesday at $64.61, close to its 52-week low of $58.00. According to TipRanks.
SEATTLE & CAMBRIDGE, United Kingdom, November 09, 2022--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, and Abcam (AIM: ABC; NASDAQ: ABCM), a global life science company working together with researchers to advance science and enable faster breakthroughs, today announced the expansion of their long-standing relationship with a new agreement to co-market Abcam antibodies for NanoString’s high-plex spatial multiomic s
Shares of life sciences research tools provider NanoString Technologies (NASDAQ:NSTG) have nosedived today owing to its disappointing third-quarter performance. While revenue dropped 20.48% year-over-year to $29.54 million, net loss expanded to $36.69 million from $31.26 million a year ago. Net loss per share at $0.79 came in wider than expectations by $0.28. During the quarter, NSTG bagged about 60 orders for spatial biology instruments clocking a 70% growth over the prior year period. The company currently has orders for over 100 CosMx systems and expects to generate revenue from them in the coming weeks.
NanoString (NSTG) delivered earnings and revenue surprises of -71.74% and 16.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
SEATTLE, November 07, 2022--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended September 30, 2022.
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
NanoString and Visiopharm Announce Collaboration to Co-develop Integrated Workflows for GeoMx and AtoMx Spatial Biology Solutions
SEATTLE, October 13, 2022--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, and Visiopharm, a world leader in AI-driven digital pathology software, today announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies. Together, NanoString and Visiopharm are developing integrated workflows leveraging the multiplexing capabil
Spatial Imaging of 1,000 RNAs and 100 Proteins Using the CosMx Spatial Molecular Imager Published in Nature Biotechnology
SEATTLE, October 12, 2022--NanoString announced the publication of its first paper describing the CosMx™ Spatial Molecular Imager’s (SMI) in Nature Biotechnology.